We will include healthy people not suffering from any diseases. We will exclude minors (less than 18 years old), pregnant women, those planning a pregnancy, and lactating women.
Conditions
Interventions
None listed
Sponsors
KAGOME CO., LTD.
Review Team Mr. Yuichiro Nakazawa, Mr. Nobuo Fuke, Mr. Yudai Aoki, Mr. Shingo Takahashi (Innovation Division, KAGOME CO., LTD.)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (Study design) We will include randomized controlled parallel trials (RCT-P), randomized controlled crossover trials (RCT-C), quasi-randomized controlled parallel trials (qRCT-P), quasi-randomized controlled crossover trials (qRCT-C), non-randomized controlled parallel trials (nonRCT-P), non-randomized controlled crossover trials (nonRCT-C), and non-randomized controlled trials. We will include scientific papers and reports which give us enough research details. (PICO) Participant: We will include healthy people not suffering from any diseases. We will exclude minors (less than 18 years old), pregnant women, those planning a pregnancy, and lactating women. Intervention: We define oral intake of Lactobacillus brevis KB290 as an intervention. Comparison: We define oral intake of test food not containing Lactobacillus brevis KB290 as controls. We also define maintaining daily life as a control. Outcome measurement: We will evaluate levels of water content in stratum corneum as primary outcome. (Language) Eligibility is not restricted by language.
Exclusion criteria
Exclusion criteria: We will exclude proceedings and unpublished studies which don't give us enough research details.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| We will evaluate the effect of Lactobacillus brevis KB290 intake on levels of water content in stratum corneum. | — |
Countries
Japan
Contacts
Public ContactTakuro Inoue
KAGOME CO., LTD. Innovation Division
Outcome results
None listed